Evidence map›Paper›PMID 30897038›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S Nowakowski and 13 more

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 225 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 6 pooled it
34.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01938001 phase3completednot on this map

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma

TypeinterventionalSponsorCelgeneRan2013 to 2022Enrolled358ConditionsLymphoma, Non-HodgkinArmsRituximab, Lenalidomide, Placebo
NCT01996865 phase3completednot on this map

A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

TypeinterventionalSponsorCelgeneRan2014 to 2024Enrolled503ConditionsLymphoma, Non-HodgkinArmsLenalidomide, Rituximab
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 6 syntheses or guidelines pooled it, 408 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. [Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 17 institutions in 9 countries.

John P Leonard1 Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
Marek Trneny2 Charles University, General Hospital, Prague, Czech Republic.
Koji Izutsu3 National Cancer Center Hospital, Tokyo, Japan.
Nathan H Fowler4 The University of Texas MD Anderson Cancer Center, Houston, TX.
Xiaonan Hong5 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Jun Zhu6 Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
Huilai Zhang7 Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
Fritz Offner8 Ghent University Hospital, Gent, Belgium.
Adriana Scheliga9 Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Grzegorz S Nowakowski10 Mayo Clinic, Rochester, MN.
Antonio Pinto11 Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Naples, Italy.
Francesca Re12 Azienda Ospedaliero Universitaria di Parma, Parma, Italy.
Laura Maria Fogliatto13 Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Phillip Scheinberg14 Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Ian W Flinn15 Sarah Cannon Research Institute, Nashville, TN.
Claudia Moreira16 Instituto Português de Oncologia do Porto Francisco Gentil Epe, Porto, Portugal.
José Cabeçadas17 Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
David Liu18 Celgene Corporation, Summit, NJ.
Stacey Kalambakas18 Celgene Corporation, Summit, NJ.
Pierre Fustier19 Celgene International, Boudry, Switzerland.
Chengqing Wu18 Celgene Corporation, Summit, NJ.
John G Gribben20 Barts Cancer Institute, London, United Kingdom.
AUGMENT Trial Investigators
Beneficência Portuguesa de São Paulo · BRBristol-Myers Squibb (Switzerland) · CHCharles University · CZCornell University · USFudan University Shanghai Cancer Center · CNGhent University Hospital · BEHospital de Clínicas de Porto Alegre · BRInstituto Nacional do Câncer · BRIPO Porto · PTIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMayo Clinic in Arizona · USOspedale di Parma · ITPeking University Cancer Hospital · CNSarah Cannon · USThe University of Texas MD Anderson Cancer Center · USTianjin Medical University Cancer Institute and Hospital · CNTokyo National Hospital · JP

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposePatients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab.

methodsA phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per independent radiology review.

resultsA total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo plus rituximab (n = 180). Infections (63%

conclusionLenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLenalidomideLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularMaleMiddle AgedNeoplasm Recurrence, LocalPlacebosRituximabLenalidomidePlacebosRituximab

Identifiers

PMID30897038
PMCPMC7035866
OpenAlexW2925270992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.